The buzz around ibogaine, a plant‑derived drug from West Africa, exploded when a U. S. president highlighted its promise at a White House event that celebrated psychedelic research. For the first time, the Food and Drug Administration has cleared a clinical trial to test the substance in people.
Doctors in the U. S. now have another tool to fight a tough cancer. The FDA gave the green light for early use of an experimental pill called daraxonrasib. It targets pancreatic ductal adenocarcinoma, a fast-spreading form of pancreatic cancer that has already resisted other treatments. Patients who
Dog owners in the U. S. might soon have a new tool to help their aging pets live healthier, longer lives. A California-based company is testing a drug called LOY-002, designed to slow down aging in dogs. Unlike typical medications that treat specific diseases like arthritis or cancer, this pill aims
A new link between sleep-tracking gadgets and birth control apps is making waves. High-end fitness watches from a major brand now share nightly skin temperature data with a fertility app approved by health regulators. The idea is simple: cooler skin at night can hint at ovulation timing, helping use
The FDA has introduced a new program that promises super-fast drug approvals. This program, called the Commissioner’s National Priority Voucher, can approve drugs in just one to two months. This is much faster than the usual 10-month review process. The idea is to prioritize drugs that match certain
A device approved by the FDA for treating ADHD in children has been found ineffective in a recent clinical trial. The external trigeminal nerve stimulator, which was expected to reduce ADHD symptoms, showed no significant improvement compared to a placebo. The FDA had initially approved the device
The U. S. Food and Drug Administration (FDA) has given the green light to a new drug called Nereus, designed to tackle motion sickness. This approval is a big deal because it's the first new treatment for this condition in over 40 years. The drug, also known as tradipitant, works by blocking a speci
Pfizer's stock took a hit recently, and it's all tied to a serious issue with one of their drugs. A patient in a long-term study for Hympavzi, a treatment for hemophilia, passed away due to severe complications. This news came out in December 2025, and it's got people talking. The patient had hemop
European markets are on a roll, hitting new highs. The Stoxx 600, DAX, and CAC 40 indexes have all seen significant gains. This year alone, the Stoxx 600 has climbed 14% higher. With just a week left, it's looking like it will be the third year in a row of growth. Investors are keeping a close eye
The FDA has recently given the green light to a wider group of women to use Addyi, a drug designed to boost sexual desire. This time, the approval is for postmenopausal women up to 65 years old. Addyi was first introduced a decade ago for premenopausal women dealing with emotional stress due to a lo
